抗感染治疗和抗菌药物管理-ASHP 2019年中会议综述

 美国卫生系统药师协会年中会议（ASHP Midyear）作为全球规模最大的药师会议之一,以发布国际前沿的临床用药研究闻名,针对医院药学领域的热点、难点提出创新和科学建议。在2019年12月召开的最近一次ASHP Midyear上,抗菌治疗和抗菌药物管理依然是关注重点,同时针对菌血症、耐甲氧西林金黄色葡萄球菌、艰难梭菌、青霉素过敏、医疗机构抗菌药物管理项目（ASP）等均发布了颇有意义的内容,以上内容同时也是国内医院抗感染领域关注的热点问题。本文就参会的启示和感想作一分享,并对笔者所在医院开展的ASP项目作一介绍。

Anti-infective therapy and antimicrobial stewardship: reviews of ASHP Midyear 2019

The American Society of Health-System Pharmacists Midyear Clinical Meeting (ASHP Midyear) is one of the largest pharmaceutical meeting in the world, featuring as reporting international advanced clinical pharmaceutical research, which puts forward innovative and scientific suggestions aiming at hotspots and difficulties in the field of hospital pharmacy. At the recent ASHP Midyear meeting held in December 2019, anti-infective therapy and antimicrobial stewardship remained a focus, meaningful contents were issued, referring to bacteremia, methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, penicillin allergy and antimicrobial stewardship program (ASP) in medical institutions, these are also hotspots in the field of anti-infection in domestic hospitals. This paper shares the enlightenment and feelings of the participants, and introduces the ASP carried out in the author's hospital.